A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386
in combination with pembrolizumab in participants with previously treated selected solid
tumors, and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination ...
Age: 18 years - 66+
Gender: All
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC)
versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Age: 12 years - 66+
Gender: All
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible
for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who have
either exhausted treatment options or are not eligible for, suitable for, or willi...
Age: 18 years - 66+
Gender: All
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to
evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in
anti-PD-1-refractory/relapsed patients with unresectable Stage III or IV melanoma. The
contributions...
Age: 18 years - 66+
Gender: All
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in
combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in
metastatic melanoma. This study will explore the Efficacy and Safety of UV1 administere...
Age: 18 years - 66+
Gender: All
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm
the safety of VV1 in combination with cemiplimab. The study will enroll patients with two
distinct advanced malignancies in separate tumor cohorts. The two cancers types ar...
Age: 18 years - 66+
Gender: All
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation and expansion trial of ATRC-101, an
engineered fully human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally
occurring human antibody. The safety, tolerability, PK, and biological activity of...
Age: 18 years - 66+
Gender: All
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for ...
Age: 12 years - 66+
Gender: All
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination
with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the most appropriate dose for the combination of
ibrutinib and pembrolizumab and to see if the combination is active for the disease. The
study will monitor for any side effects and if the combination of ibrutinib and pembro...
Age: 18 - 99 years
Gender: All
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The purpose of this study is to test the effectiveness of a drug called pembrolizumab in
patients with Myeloproliferative Neoplasm (MPN); chronic phase (MF-CP), accelerated phase
(MPN-AP), or blast phase (MF-BP). Myelofibrosis neoplasm (MPN) is a group of diseases of ...
Age: 18 years - 66+
Gender: All
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
The purpose of this study is to determine the initial safety profile and initial antitumor
activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab]
with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 ...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
This phase I trial studies the side effects of pembrolizumab in treating patients with human
immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not
respond to treatment (refractory), or have distributed over a large area in the b...
Age: 18 years - 66+
Gender: All